| A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | AA | AB | AC | AD | AE | AF | AG | AH | AI | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | Royalty | Other Sales Compensation | Deal Date | R&D | Client | EFR$200M (%) | EFR$500M (%) | EFR$1B (%) | Deal Size ($M) | Maximum Share (%) | Deal Subject | Exclusivity | Deal Type | Stage | Disease | Indication | Technology | Sub-Technology | Upfront Cash ($M) | Upfront Equity ($M) | Contingent Equity ($M) | R&D Support ($M) | FTE Rate ($M) | Loan ($M) | Dev / Reg Milestones ($M) | Other Milestones ($M) | Total Precommercial Payments ($M) | Sales Milestones ($M) | Marketing Fee (%) | Transfer Price (%) | Manufacture Cost + (%) | Profit Split (%) | Licensor Category | Licensee Category | Territory |
2 | Tag | 11/2016 | TetraLogic Pharmaceuticals | Medivir | 5.00 | 5.00 | 6.25 | 165.00 | 10.00 | Remetinostat for lymphoma and birinapant for solid tumors | Exclusive | Asset Purchase | Phase II | Cancer | Lymphoma, Solid Tumors | Drug Delivery, Synthetics | Small Molecule | 12.00 | 7.00 | 25.00 | 44.00 | 121.00 | 2013-15 IPOs | Worldwide | |||||||||||
3 | Tag | 9/2016 | Viventia | Eleven Biotherapeutics | 2.00 | 2.00 | 2.00 | 36.00 | 2.00 | Acquisition for shares | Exclusive | Acquisition, Equity | Phase III | Cancer | Broad Focus Cancer | Monoclonals, Recombinant DNA | Conjugates | 13.50 | 22.50 | 36.00 | 2013-15 IPOs | Worldwide | |||||||||||||
4 | Tag | 6/2016 | Eleven Biotherapeutics | Roche | 7.50 | 7.50 | 7.50 | 270.00 | EBI-031 (IL-6 antagonist antibody) for diabetic macular edema and uveitis | Exclusive | License, Option | Preclinical | Ophthalmic | Broad Focus Ophthalmic | Monoclonals | Humanized Abs | 7.50 | 197.50 | 65.00 | 270.00 | 2013-15 IPOs | Top Pharma | Worldwide | ||||||||||||
5 | Tag | 6/2016 | Taxus Cardium Pharmaceuticals, Angionetics | Huapont Life Sciences | 5.75 | 7.30 | 8.65 | 3.00 | 10.00 | Generx (Ad5FGF-4) for cardio in mainland China | Exclusive | Distribution, Equity | Phase III | Cardiovascular | Angina, Myocardial Infarction | Oligonucleotides | Gene Therapy | 1.00 | 2.00 | 3.00 | 20.00 | Asia | |||||||||||||
6 | Tag | 5/2016 | Immune Pharmaceuticals | Novel Pain Therapeutics | 7.50 | 8.75 | 9.38 | 161.00 | 10.00 | AmiKet and AmiKet Nano for peripheral neuropathic pain | Exclusive | Development, Equity, License, Option | Phase II, Formulation | Central Nervous System | Pain | Drug Delivery, Synthetics | Small Molecule, Topical | 15.00 | 1.00 | 25.00 | 41.00 | 120.00 | Worldwide | ||||||||||||
7 | Tag | 5/2016 | Nektar Therapeutics | Daiichi Sankyo | 20.00 | 20.00 | 20.00 | 80.00 | 20.00 | Onzeald (etirinotecan pegol Topo-1 inhib) for breast and brain cancer in Europe & Turkey | Exclusive | Co-Development, License, Supply | Phase III | Cancer | Brain, Breast | Drug Delivery, Synthetics | PEG Products | 20.00 | 35.00 | 55.00 | 25.00 | Japanese Pharma | Europe, Middle East | ||||||||||||
8 | Tag | 1/2016 | Hebrew University, Yissum Research Development | Immune Pharmaceuticals | 5.00 | 5.00 | 5.00 | 5.33 | 5.00 | Topical delivery of Cyclosporine A by means of biodegradable
nanoparticles | Exclusive | Development, Equity, License, Research | Preclinical | Drug Delivery, Synthetics | Small Molecule, Topical | 0.53 | 0.30 | 3.50 | 1.00 | 5.33 | Research Institution | Worldwide | |||||||||||||
9 | Tag | 7/2015 | Johns Hopkins | Progenics Pharmaceuticals | 3.00 | 3.00 | 3.00 | 2.40 | 3.00 | PyL fluorinated PSMA-targeted PET imaging for prostate cancer ex-Oceania | Exclusive | License | Diagnostic | Cancer | Diagnosis - Contrast/Imaging, Prostate | Diagnostics | 0.15 | 1.25 | 1.00 | 2.40 | Research Institution | Africa, Asia, Europe, Middle East, NAFTA, South America | |||||||||||||
10 | Tag | 7/2015 | Lonza | CytoDyn | 2.00 | 2.00 | 2.00 | 2.00 | Glutamine synthetase expression of PRO 140 monoclonal for HIV | Non-exclusive | License | Discovery | Infectious-Viral | Human Immunodeficiency Virus/HIV | Monoclonals | Worldwide | |||||||||||||||||||
11 | Tag | 6/2015 | Hebrew University, Yissum Research Development | Immune Pharmaceuticals | 3.00 | 3.00 | 3.00 | 4.93 | 3.00 | Topical nano-formulation of AmiKet for pain | Exclusive | License, Research | Formulation | Central Nervous System | Pain | Drug Delivery, Synthetics | Small Molecule, Topical | 0.03 | 0.40 | 4.50 | 4.93 | Research Institution | Worldwide | ||||||||||||
12 | Tag | 6/2015 | Intrexon | Oragenics | 12.00 | 12.00 | 12.00 | 37.00 | 12.00 | AG013 (oral rinse of Trefoil Factor 1) for chemo-induced mucositis | Exclusive | Development, Equity, License, Loan | Phase II | Dental/Oral | Mucositis | Peptides | 5.00 | 22.00 | 10.00 | 37.00 | 2013-15 IPOs | Worldwide | |||||||||||||
13 | Tag | 3/2015 | Oxis International, Oxis Biotech | MultiCell Immunotherapeutics | 3.00 | 3.00 | 3.00 | 15.88 | 3.00 | Three antibody-drug conjugate products containing OXS-2175 and OXS-4235 for cancer | Exclusive | License, Research | Discovery | Cancer | Breast, Multiple Myeloma | Monoclonals, Synthetics | Conjugates, Small Molecule | 0.50 | 1.13 | 4.25 | 10.00 | 15.88 | Worldwide | ||||||||||||
14 | Tag | 12/2014 | GlaxoSmithKline | Axovant, Roivant Neurosciences | 12.50 | 12.50 | 12.50 | 165.00 | 12.50 | RVT-101 (SB742457 selective 5-HT6 receptor antagonist) for Alzheimer's | Exclusive | Asset Purchase | Phase II | Central Nervous System | Alzheimer's Disease | Synthetics | Small Molecule | 5.00 | 75.00 | 80.00 | 85.00 | Top Pharma | 2013-15 IPOs | Worldwide | |||||||||||
15 | Tag | 12/2014 | Nuo Therapeutics | Rohto Pharmaceutical | 9.00 | 9.00 | 9.00 | 4.00 | 9.00 | Aurix platelet and plasma therapy system for wound care in Japan | Exclusive | Distribution, License | Filed, Device | Dermatologic | Wound Healing | Cell Therapy - Stem Cells/Factors | 3.00 | 1.00 | 4.00 | 10.00 | Japanese Pharma | Asia | |||||||||||||
16 | Tag | 11/2014 | Lonza, Cutanogen | Amarantus Bioscience | 2.00 | 2.00 | 2.00 | 9.25 | 2.00 | Option to purchase Engineered Skin Substitute (ESS) for burns | Exclusive | Acquisition, Option, Settlement | Phase I | Dermatologic | Burns | Cell Therapy - Stem Cells/Factors, Natural Product | 0.25 | 9.00 | 9.25 | Worldwide | |||||||||||||||
17 | Tag | 10/2014 | Sorrento Therapeutics | Lee’s Pharmaceutical, China Oncology Focus Limited | 8.20 | 9.28 | 9.64 | 50.10 | 10.00 | STI-A1014 (anti-PD-L1 human MAb) in China | Exclusive | Equity, License | Phase II, Phase I | Cancer | Broad Focus Cancer | Monoclonals | Human Abs | 1.00 | 3.60 | 3.00 | 0.50 | 8.10 | 42.00 | Asia | |||||||||||
18 | Tag | 9/2014 | Johns Hopkins | Second Sight | 0.25 | 0.25 | 0.25 | 4.04 | 0.25 | Retinal prosthesis | Non-exclusive | Equity, License, Research | Device | Ophthalmic | Broad Focus Ophthalmic | Device | 4.04 | Research Institution | 2013-15 IPOs | Worldwide | |||||||||||||||
19 | Tag | 6/2014 | Dartmouth College | Celyad, Celdara Medical | 2.00 | 2.00 | 2.00 | 1.63 | 2.00 | Anti-B7-H6 Immunotherapies | Exclusive | Development, License | Cancer | 0.03 | 1.60 | 1.63 | Research Institution | 2013-15 IPOs | Worldwide | ||||||||||||||||
20 | Tag | 6/2014 | University of Illinois | RespireRx Pharmaceuticals | 4.00 | 4.00 | 4.00 | 2.40 | 4.00 | IP related to use of cannabinoids for sleep related breathing disorders | Exclusive | License | Lead Molecule | Central Nervous System | Sleep Disorders | Synthetics | Small Molecule | 0.48 | 1.93 | 2.40 | Research Institution | Worldwide | |||||||||||||
21 | Tag | 2/2014 | Celladon | Servier | 3.00 | 3.00 | 3.00 | 107.10 | 3.00 | Option to small molecule SERCA2b modulators for metabolic diseases, including type 2 diabetes, ex-US | Exclusive | Letter of Intent, License, Option, Research | Discovery | Endocrinological & Metabolic | Broad Focus Endocrinological & Metabolic, Diabetes | Synthetics | Small Molecule | 2.70 | 78.40 | 26.00 | 107.10 | 2013-15 IPOs | Mid Tier Pharma | Africa, Asia, Europe, Middle East, NAFTA, South America | |||||||||||
22 | Tag | 1/2014 | Napo Pharmaceuticals | Jaguar Animal Health | 10.00 | 10.00 | 10.00 | 5.15 | 10.00 | SP-303 (crofelemer) medicinal plant extract for veterinary usage | Exclusive | License | Other | Other/Miscellaneous | Veterinary | Natural Product | 1.00 | 2.15 | 3.15 | 2.00 | Worldwide | ||||||||||||||
23 | Tag | 1/2014 | PsychoGenics | Amarantus Bioscience | 8.00 | 8.00 | 8.00 | 5.25 | 8.00 | Eltoprazine for Levadopa induced dyskinesia associated with Parkinson's ex-Japan, China & Korea | Exclusive | License | Phase II, Orphan Indication | Central Nervous System | Parkinson's Disease | Synthetics | Small Molecule | 0.75 | 4.50 | 5.25 | Africa, Asia, Europe, Middle East, NAFTA, South America | ||||||||||||||
24 | Tag | 11/2013 | Egalet | Shionogi | 8.00 | 10.70 | 11.60 | 350.00 | 12.50 | Abuse-deterrent oral hydrocodone opioid product | Exclusive | Development, Equity, License, Termination | Preclinical, Formulation | Central Nervous System | Pain | Drug Delivery, Synthetics | Oral, Small Molecule | 10.00 | 15.00 | 0.25 | 60.00 | 80.00 | 165.00 | 185.00 | 2013-15 IPOs | Japanese Pharma | Worldwide | ||||||||
25 | Tag | 11/2013 | Endo International, Paladin Labs | Knight Therapeutics | 22.50 | 22.50 | 22.50 | 9.80 | 22.50 | Spin-out of Impavido (miltefosine) for leishmaniasis ex-US | Exclusive | Asset Purchase, Equity, License | Approved | Infectious-Miscellaneous | Parasitic-Miscellaneous | Synthetics | Small Molecule | Africa, Asia, Europe, Middle East, NAFTA, South America | |||||||||||||||||
26 | Tag | 11/2013 | Pozen | Horizon Pharma | 10.00 | 10.00 | 10.00 | 10.00 | Vimovo (naproxen/esomeprazole magnesium) for arthritis and ankylosing spondylitis in US | Exclusive | License | Autoimmune/Inflammatory | Rheumatoid Arthritis | NAFTA | |||||||||||||||||||||
27 | Tag | 10/2013 | Nerviano Medical Sciences | Ignyta | 6.50 | 6.50 | 6.80 | 113.00 | 12.00 | Entrectinib (tyrosine kinase Trk inhibitor) plus ROS1 & ALK targets for cancer | Exclusive | Development, License, Warrant | Phase I, Preclinical | Cancer | Broad Focus Cancer, Solid Tumors | Synthetics | Small Molecule | 7.00 | 1.00 | 55.00 | 50.00 | 113.00 | 2013-15 IPOs | Worldwide | |||||||||||
28 | Tag | 10/2013 | VIVUS | Endo International, Auxilium | 9.50 | 13.40 | 15.70 | 300.00 | 18.00 | Stendra (avanafil) PDE-5 inhibitor for erectile dysfunction in NA | Exclusive | Co-Development, License, Supply, Termination | Approved | Genitourinary/Gynecologic | Sexual Dysfunction | Synthetics | Small Molecule | 30.00 | 15.00 | 45.00 | 255.00 | 10.00 | NAFTA | ||||||||||||
29 | Tag | 8/2013 | Green Molecular | ChromaDex | 4.00 | 4.00 | 4.00 | 0.11 | 4.00 | IP covering topical application of pTeroPure pterostilbene for dermatologic & skin cancer prevention | Exclusive | License | Formulation | Cancer, Dermatologic | Broad Focus Dermatologic, Melanoma | Drug Delivery, Natural Product | Topical | 0.03 | 0.08 | 0.11 | Worldwide | ||||||||||||||
30 | Tag | 8/2013 | University of New South Wales | Benitec | 3.00 | 3.00 | 3.00 | 0.83 | 3.00 | Tribetarna program therapy for lung cancer | Exclusive | License | Preclinical | Cancer | Lung | Oligonucleotides | RNAi | 0.03 | 0.80 | 0.83 | Research Institution | 2013-15 IPOs | Worldwide | ||||||||||||
31 | Tag | 7/2013 | Array BioPharma | Loxo Oncology | 7.00 | 7.00 | 7.00 | 450.25 | 7.00 | Small molecules to p70S6 kinase, telomerase reverse transcriptase, FGF & Trk receptors for cancer | Exclusive | Development, Equity, License, Research | Lead Molecule, Discovery | Cancer | Broad Focus Cancer | Synthetics | Small Molecule | 15.00 | 72.00 | 63.25 | 150.25 | 300.00 | 2013-15 IPOs | Worldwide | |||||||||||
32 | Tag | 7/2013 | Medistem | Cytori | 3.50 | 3.50 | 3.50 | 0.01 | 3.50 | Stem cell mediated treg activation IP for treatment of autoimmune diseases | Exclusive | License | Discovery | Autoimmune/Inflammatory | Broad Focus Autoimmune/Inflammatory | Cell Therapy - Stem Cells/Factors | 0.01 | 0.01 | NAFTA | ||||||||||||||||
33 | Tag | 7/2013 | Nuvo Research | Warner Chilcott, Actavis, Allergan, Galen Limited | 10.00 | 10.00 | 10.00 | 14.50 | 10.00 | Synera (topical patch of lidocaine& tetracaine) for dermal pain in US | Exclusive | License | Approved, Formulation | Central Nervous System | Pain | Drug Delivery | Transdermal | 4.50 | 4.50 | 10.00 | Mid Tier Pharma | NAFTA | |||||||||||||
34 | Tag | 7/2013 | OptiNose | Otsuka Pharmaceutical, Avanir Pharmaceuticals | 11.50 | 13.00 | 13.50 | 110.00 | 14.00 | Intranasal delivery system containing low-dose triptan powder for migraine in NAFTA | Exclusive | Co-Development, License | Phase III, Formulation | Central Nervous System | Migrane | Drug Delivery | Nasal | 20.00 | 40.00 | 60.00 | 50.00 | Japanese Pharma | NAFTA | ||||||||||||
35 | Tag | 7/2013 | University Of Guelph | Stellar Biotechnologies | 4.60 | 4.60 | 4.60 | 71.04 | 4.60 | Polysaccharides as immunotherapies and diagnostics for Clostridium difficile infection | Exclusive | Development, Equity, License | Preclinical | Infectious-Bacterial | Carbohydrates, Diagnostics | 0.25 | 0.30 | 6.75 | 0.07 | 71.04 | 63.68 | Research Institution | Worldwide | ||||||||||||
36 | Tag | 6/2013 | Ben Gurion University, B.G. Negev Technologies | Sorrento Therapeutics | 1.00 | 1.00 | 1.00 | 1.60 | 1.00 | Development of anti-viral antibodies | Exclusive | Development, License, Option, Research | Phase I | Infectious-Viral | Broad Focus Infectious-Viral | Monoclonals | Humanized Abs | 1.60 | Research Institution | Worldwide | |||||||||||||||
37 | Tag | 6/2013 | Resverlogix | RVX Therapeutics | 1.00 | 1.80 | 3.00 | 5.00 | Compounds for cardio disease excluding Apo A-1 | Exclusive | License | Lead Molecule | Cardiovascular | Broad Focus Cardiovascular | Worldwide | ||||||||||||||||||||
38 | Tag | 5/2013 | Aradigm | Grifols | 12.50 | 15.50 | 17.75 | 116.00 | 20.00 | Inhaled ciprofloxacin (Pulmaquin and Lipoquin) for respiratory diseases | Exclusive | Co-Development, Equity, License, Option | Phase II, Formulation | Respiratory | Bronchitis, Cystic Fibrosis | Drug Delivery, Synthetics | Liposomes, Small Molecule | 26.00 | 65.00 | 25.00 | 116.00 | Mid Tier Pharma | Worldwide | ||||||||||||
39 | Tag | 5/2013 | Eleven Biotherapeutics | ThromboGenics | 3.00 | 3.00 | 3.00 | 29.20 | 3.00 | Protein therapeutic targeting Slit, Robo or Flrt targets for diabetic macular edema | Exclusive | License, Research | Discovery | Ophthalmic | Other Ophthalmic | Peptides | 1.75 | 2.45 | 0.35 | 25.00 | 29.20 | 2013-15 IPOs | Worldwide | ||||||||||||
40 | Tag | 5/2013 | Stanford | Fate Therapeutics | 4.00 | 4.00 | 4.00 | 1.52 | 4.00 | Wnt proteins for stem cell modulation | Exclusive | Development, Equity, License | Discovery | Hematologic, Transplantation | Broad Focus Hematologic, Broad Focus Transplantation | Cell Therapy - Stem Cells/Factors | 0.52 | 1.00 | 1.52 | Research Institution | 2013-15 IPOs | Worldwide | |||||||||||||
41 | Tag | 4/2013 | Bind Therapeutics | AstraZeneca | 3.50 | 3.50 | 4.25 | 197.00 | 10.00 | AZD2811 (metabolite of the prodrug barasertib) selective inhibitor of Aurora B kinase for cancer | Exclusive | Development, License, Option | Preclinical, Formulation | Cancer | Broad Focus Cancer | Drug Delivery | Other | 4.00 | 0.33 | 71.00 | 97.00 | 172.00 | 25.00 | 2013-15 IPOs | Top Pharma | Worldwide | |||||||||
42 | Tag | 4/2013 | Cara Therapeutics | Maruishi Pharmaceutical | 13.75 | 17.50 | 18.75 | 43.50 | 20.00 | CR845 (kappa opioid receptor agonist) for pain & uremic pruritus in Japan | Exclusive | Equity, License, Supply | Phase II | Central Nervous System, Renal | Other Renal, Pain | Peptides | 15.00 | 8.00 | 4.50 | 6.00 | 33.50 | 10.00 | 10.00 | 2013-15 IPOs | Japanese Pharma | Asia | |||||||||
43 | Tag | 4/2013 | Concert Pharmaceuticals | Celgene | 5.00 | 5.00 | 5.50 | 355.50 | 10.00 | CDP-730 (PDE4 inhibitor) deuterium-apremilast targeting cancer and inflammation | Exclusive | Co-Development, License, Option | Preclinical | Autoimmune/Inflammatory, Cancer | Broad Focus Autoimmune/Inflammatory, Broad Focus Cancer | Synthetics | Small Molecule | 35.00 | 133.00 | 137.50 | 305.50 | 50.00 | 2013-15 IPOs | Major Biotech | Worldwide | ||||||||||
44 | Tag | 4/2013 | Medtronic | NuVasive | 4.00 | 4.00 | 4.00 | 7.50 | 4.00 | Anterior cervical plate products and systems | Non-exclusive | License, Settlement | Device | Bone Disease | Other Bone Disease | Device | 7.50 | 7.50 | Worldwide | ||||||||||||||||
45 | Tag | 3/2013 | Bind Therapeutics | Pfizer | 2.00 | 2.00 | 2.50 | 403.00 | 9.00 | Accurin nanoparticle-encapsulated MEK and PK1 compounds for cancer | Exclusive | Development, License, Option | Preclinical, Formulation | Cancer | Broad Focus Cancer | Drug Delivery, Synthetics | Other, Small Molecule | 4.00 | 0.33 | 99.50 | 179.50 | 283.00 | 120.00 | 2013-15 IPOs | Top Pharma | Worldwide | |||||||||
46 | Tag | 3/2013 | Intrexon | AmpliPhi Biosciences | 8.00 | 9.60 | 9.80 | 10.50 | 10.00 | Bacteriophage therapies for antibiotic resistant infections | Exclusive | Equity, License, Research, Termination | Discovery | Infectious-Bacterial | Broad Focus Infectious-Bacterial | Cell Therapy - Stem Cells/Factors | 3.00 | 7.50 | 10.50 | 2013-15 IPOs | Worldwide | ||||||||||||||
47 | Tag | 3/2013 | Ligand, CyDex | Spectrum Pharmaceuticals | 20.00 | 20.00 | 20.00 | 69.00 | 20.00 | Captisol-enabled propylene glycol-free Melphalan | Exclusive | Development, License | Phase II, Formulation, Orphan Indication | Cancer, Transplantation | Multiple Myeloma, Stem Cell/Bone Marrow | Synthetics | Small Molecule | 3.00 | 6.00 | 9.00 | 60.00 | Worldwide | |||||||||||||
48 | Tag | 3/2013 | Washington University | ChromaDex | 4.00 | 4.00 | 4.00 | 0.70 | 4.00 | Nicotinamide Riboside for treatment of neuropathies caused by axon degeneration | Exclusive | Development, License | Other/Miscellaneous | Nutritionals/Vitamins | Natural Product | 0.14 | 0.47 | 0.08 | 0.70 | Research Institution | Worldwide | ||||||||||||||
49 | Tag | 2/2013 | Concert Pharmaceuticals | Jazz Pharmaceuticals | 6.00 | 7.50 | 9.05 | 126.10 | 11.00 | JPZ-386 (D-SXB deuterium-modified sodium oxybate) for narcolepsy | Exclusive | Development, License | Preclinical, Orphan Indication | Central Nervous System | Sleep Disorders | Synthetics | Small Molecule | 4.00 | 0.32 | 38.00 | 12.50 | 54.50 | 70.00 | 2013-15 IPOs | Worldwide | ||||||||||
50 | Tag | 2/2013 | Elan | Biogen | 18.00 | 18.00 | 18.00 | 3,249.00 | 25.00 | Full ownership of Tysabri (natalizumab) for multiple sclerosis | Exclusive | Asset Purchase, License | Approved, Orphan Indication | Central Nervous System | Multiple Sclerosis | Monoclonals | Humanized Abs | 3,249.00 | Mid Tier Pharma | Major Biotech | Worldwide | ||||||||||||||
51 | Tag | 1/2013 | Bind Therapeutics | Amgen | 5.00 | 5.25 | 6.38 | 187.50 | 11.00 | Accurin nanoparticle-encapsulation of AMG-208 kinase inhibitor for solid tumors | Exclusive | Development, License, Option, Termination | Preclinical, Formulation | Cancer | Solid Tumors | Drug Delivery | Other | 2.00 | 0.33 | 116.50 | 19.00 | 137.50 | 50.00 | 2013-15 IPOs | Major Biotech | Worldwide | |||||||||
52 | Tag | 1/2013 | Yale | Bind Therapeutics | 0.25 | 0.25 | 0.25 | 1.01 | 0.25 | Targeted and high density drug-loaded polymeric materials for treatment of cancer | Exclusive | Development, License | Discovery | Cancer | Broad Focus Cancer | Synthetics | Small Molecule | 0.50 | 0.25 | 0.26 | 1.01 | Research Institution | 2013-15 IPOs | Worldwide | |||||||||||
53 | Tag | 9/2012 | Ligand, CyDex | MEI Pharma | 3.00 | 3.00 | 3.00 | 4.70 | 3.00 | Captisol with ME-143 & ME-344 (isoflavone-based drug compounds) for improved solubility | Exclusive | License, Supply | Lead Molecule, Formulation | Unlimited | Drug Delivery | Oral | 0.08 | 2.63 | 2.00 | 4.71 | Worldwide | ||||||||||||||
54 | Tag | 8/2012 | Bristol-Myers Squibb | Synergy Pharmaceuticals | 5.00 | 5.00 | 5.00 | 10.40 | 5.00 | FV-100 bicyclic nucleoside analogue for shingles | Exclusive | Asset Purchase | Phase II | Infectious-Viral | Other Infectious-Viral | Synthetics | Small Molecule | 1.40 | 3.00 | 4.40 | 6.00 | Top Pharma | Worldwide | ||||||||||||
55 | Tag | 8/2012 | S*BIO | MEI Pharma | 2.00 | 2.00 | 2.00 | 76.20 | 2.00 | Pracinostat HDAC inhibitor for solid tumors and hematologic disorders | Exclusive | Asset Purchase, Equity | Phase II | Cancer, Hematologic | Leukemia, Lymphoma, Other Hematologic, Solid Tumors | Synthetics | Small Molecule | 0.50 | 0.50 | 30.20 | 15.00 | 46.20 | 30.00 | Worldwide | |||||||||||
56 | Tag | 7/2012 | Aspen Bio | Ceva Sante Animale | 10.00 | 10.00 | 10.00 | 4.80 | 10.00 | Single chain reproductive hormone technology for livestock reproduction | Exclusive | License | Other | Other/Miscellaneous | Veterinary | Recombinant DNA | 0.80 | 2.00 | 2.00 | 4.80 | Worldwide | ||||||||||||||
57 | Tag | 7/2012 | Dartmouth College | ChromaDex | 3.00 | 3.00 | 3.00 | 0.16 | 3.00 | IP covering pharmaceutical use of nicotinamide riboside | Exclusive | Development, License | Other/Miscellaneous | Nutritionals/Vitamins | Natural Product | 0.09 | 0.03 | 0.16 | 0.05 | Research Institution | Worldwide | ||||||||||||||
58 | Tag | 7/2012 | Juniper Pharmaceuticals | Scientelle | 3.00 | 3.00 | 3.00 | 3.00 | Peroxides for bacterial vaginosis | Exclusive | License | Lead Molecule | Genitourinary/Gynecologic | Other Genitourinary/Gynecologic | Worldwide | ||||||||||||||||||||
59 | Tag | 7/2012 | Progenics Pharmaceuticals | CytoDyn | 5.00 | 5.00 | 5.00 | 10.00 | 5.00 | PRO 140 (humanized MAb HIV viral entry inhibitor) to treat HIV | Exclusive | Asset Purchase | Phase II | Infectious-Viral | Human Immunodeficiency Virus/HIV | Monoclonals | Humanized Abs | 3.50 | 6.50 | 10.00 | Worldwide | ||||||||||||||
60 | Tag | 6/2012 | Aegis Therapeutics | Biodel | 2.38 | 3.25 | 4.38 | 22.12 | 6.00 | ProTek and Intravail technologies for formulations of glucagon to treat diabetes | Exclusive | License | Formulation | Endocrinological & Metabolic | Diabetes | Drug Delivery | Other | 0.37 | 5.25 | 4.00 | 9.62 | 12.50 | Worldwide | ||||||||||||
61 | Tag | 6/2012 | University of California, UC San Francisco | uniQure | 1.25 | 1.25 | 1.25 | 0.30 | 1.25 | GDNF.AAV2 gene therapy for Parkinson's disease | Non-exclusive | Development, License | Preclinical, Orphan Indication | Central Nervous System | Parkinson's Disease | Oligonucleotides | Gene Therapy | 0.30 | 0.30 | Research Institution | 2013-15 IPOs | Worldwide | |||||||||||||
62 | Tag | 5/2012 | Marina Biotech | Monsanto | 2.00 | 2.00 | 2.00 | 1.50 | 2.00 | Oligonucleotide delivery systems for siRNA compounds in plants | Exclusive | License, Research | Other | Other/Miscellaneous | Agriculture | Oligonucleotides | Ligands | 1.25 | 0.25 | 1.50 | Worldwide | ||||||||||||||
63 | Tag | 5/2012 | Mass General Hospital | ProQR Therapeutics | 2.00 | 2.00 | 2.00 | 0.01 | 2.00 | Novel therapeutics for treatment of cystic fibrosis | Exclusive | Development, License | Preclinical, Orphan Indication | Respiratory | Cystic Fibrosis | 0.01 | Research Institution | 2013-15 IPOs | Worldwide | ||||||||||||||||
64 | Tag | 5/2012 | Merck | Tesaro | 10.00 | 10.60 | 11.90 | 181.00 | 14.00 | Niraparib (MK-4827) PARP inhibitor and backup compound, MK-2512 for cancer | Exclusive | Co-Promotion, License | Phase I | Cancer | Broad Focus Cancer | Synthetics | Small Molecule | 7.00 | 57.00 | 29.50 | 93.50 | 87.50 | Top Pharma | Worldwide | |||||||||||
65 | Tag | 4/2012 | University of Texas | Moleculin | 3.50 | 3.80 | 3.90 | 1.58 | 4.00 | Novel cancer therapeutic | Exclusive | Development, License | Phase I | Cancer | Broad Focus Cancer | 0.33 | 1.25 | 1.58 | Research Institution | Worldwide | |||||||||||||||
66 | Tag | 3/2012 | PerkinElmer, Caliper Life Sciences | GenMark Diagnostics | 3.00 | 3.30 | 3.50 | 4.20 | 3.50 | Diagnostic applications of microfluidic technology | Non-exclusive | License | Diagnostic | Unlimited | Diagnostics | DNA Probes | 0.40 | 2.00 | 2.40 | 1.80 | Worldwide | ||||||||||||||
67 | Tag | 3/2012 | RegeneRx Biopharmaceuticals | Lee’s Pharmaceutical | 6.55 | 6.22 | 6.00 | 4.00 | 10.00 | Thymosin Beta 4-based products for ophthalmic and cardio diseases in China | Exclusive | Letter of Intent, License | Phase II | Cardiovascular, Ophthalmic | Broad Focus Cardiovascular, Broad Focus Ophthalmic | Peptides | 0.40 | 0.50 | 0.90 | 3.10 | Asia | ||||||||||||||
68 | Tag | 3/2012 | University of Pittsburgh | Stemline Therapeutics | 5.00 | 5.00 | 5.00 | 0.33 | 5.00 | IND data for dendrite and glioma peptide trial | Non-exclusive | License | Preclinical, Orphan Indication | Cancer | Brain, Other Cancer | Peptides | 0.03 | 0.30 | 0.33 | Research Institution | 2013-15 IPOs | Worldwide | |||||||||||||
69 | Tag | 3/2012 | Yale | Medistem | 2.00 | 2.00 | 2.00 | 1.15 | 2.00 | Endometrial derived stem cells to treat diabetes | Exclusive | Development, License | Preclinical | Endocrinological & Metabolic | Diabetes | Cell Therapy - Stem Cells/Factors | 0.05 | 1.10 | 1.15 | Research Institution | Worldwide | ||||||||||||||
70 | Tag | 2/2012 | Concert Pharmaceuticals | Otsuka Pharmaceutical, Avanir Pharmaceuticals | 6.00 | 6.40 | 7.20 | 256.00 | 10.00 | AVP-786 (deuterium-modified dextromethorphan) for neurological and psychiatric disorders | Exclusive | Development, License | Preclinical | Central Nervous System, Psychiatric | Broad Focus Central Nervous System, Broad Focus Psychiatric | Synthetics | Small Molecule | 2.00 | 0.30 | 56.00 | 73.00 | 131.00 | 125.00 | 2013-15 IPOs | Japanese Pharma | Worldwide | |||||||||
71 | Tag | 2/2012 | Sheba Medical Center | Orgenesis | 3.50 | 3.50 | 3.50 | 3.08 | 3.50 | Methods of inducing regulated pancreatic hormone production in islet cells for diabetes | Exclusive | License | Discovery | Endocrinological & Metabolic | Diabetes | Cell Therapy - Stem Cells/Factors | 0.08 | 1.00 | 1.08 | 2.00 | Research Institution | Worldwide | |||||||||||||
72 | Tag | 1/2012 | Health Discovery | NeoGenomics | 6.50 | 6.50 | 6.50 | 8.00 | 6.50 | genomic biomarkers for prostate & other cancers | Exclusive | Equity, License | Diagnostic, Reagent | Cancer | Broad Focus Cancer, Prostate | Diagnostics | 1.00 | 2.00 | 3.00 | 5.00 | Worldwide | ||||||||||||||
73 | Tag | 1/2012 | NIH | KineMed | 3.87 | 3.95 | 4.48 | 18.04 | 5.00 | 5a peptide for cardio vascular diseases | Exclusive | License | Preclinical | Cardiovascular | Angina, Atherosclerosis/Coronary Artery Disease, Congestive Heart Failure, Myocardial Infarction, Other Cardiovascular, Peripheral Arterial Disease | Peptides | 0.29 | 3.75 | 11.04 | 7.00 | Research Institution | Worldwide | |||||||||||||
74 | Tag | 1/2012 | Uluru | Melmed Holdings | 10.00 | 10.00 | 10.00 | 0.25 | 40.00 | Altrazeal wound healing device in Europe, Mideast, Africa and Oceania | Exclusive | License, Supply | Device | Dermatologic | Wound Healing | Device | 0.25 | 0.25 | 30.00 | Africa, Asia, Europe, Middle East | |||||||||||||||
75 | Tag | 12/2011 | Texas A&M | Oragenics | 5.00 | 5.00 | 5.00 | 0.71 | 5.00 | Site directed mutagenesis of Mutacin 1140 | Exclusive | Development, License | Preclinical | Peptides | 0.01 | 0.70 | 0.71 | Research Institution | Worldwide | ||||||||||||||||
76 | Tag | 11/2011 | Intrexon | Lilly, Elanco | 10.50 | 11.40 | 11.70 | 3.40 | 12.00 | Novel canine IL-12, IL-1ra & Insulin, feline Insulin & equine IL-1ra compounds | Exclusive | License, Research | Discovery | Other/Miscellaneous | Veterinary | Recombinant DNA | 0.15 | 1.00 | 2.25 | 3.40 | 2013-15 IPOs | Top Pharma | Worldwide | ||||||||||||
77 | Tag | 11/2011 | Leukemia & Lymphoma Society | Curis | 5.00 | 5.00 | 5.00 | 1.50 | 5.00 | Oral small molecule dual Pi3K and HDAC inhibitor CUDC-907 for B-cell lymphoma and multiple myeloma | Exclusive | Development, License, Research | Preclinical, Orphan Indication | Cancer | Lymphoma, Multiple Myeloma | Drug Delivery, Synthetics | Oral, Small Molecule | 4.00 | 1.50 | 1.50 | Research Institution | Worldwide | |||||||||||||
78 | Tag | 10/2011 | GlycoMimetics | Pfizer | 10.00 | 10.00 | 10.90 | 332.50 | 13.00 | GMI-1070 pan-selectin antagonist for vaso-occlusive crisis associated with sickle cell disease | Exclusive | Co-Development, License, Loan | Phase II, Orphan Indication | Hematologic | Sickle Cell Disease | Synthetics | Small Molecule | 22.50 | 110.00 | 65.00 | 197.50 | 135.00 | 2013-15 IPOs | Top Pharma | Worldwide | ||||||||||
79 | Tag | 10/2011 | Rosetta Genomics | Avatao Biotech | 3.00 | 3.00 | 3.00 | 8.30 | 3.00 | miRview microRNA metastatic cancer diagnostic tests in China | Exclusive | License | Diagnostic | Cancer | Broad Focus Cancer | Diagnostics | DNA Probes | 0.60 | 0.20 | 0.80 | 7.50 | Asia | |||||||||||||
80 | Tag | 9/2011 | Children’s Cancer Institute Australia | Cleveland BioLabs, Panacela Labs | 2.00 | 2.00 | 2.00 | 6.50 | 2.00 | Small Molecules Inhibiting Oncoprotein MYC for solid tumor treatment | Exclusive | Equity, License, Option | Preclinical | Cancer | Solid Tumors | Synthetics | Small Molecule | 6.50 | 6.50 | Research Institution | Worldwide | ||||||||||||||
81 | Tag | 9/2011 | Concert Pharmaceuticals | Teva, Auspex Pharmaceuticals | 2.50 | 2.50 | 2.50 | 2.50 | Patent assignment related to deuterated pirfenidone | Exclusive | Assignment, License | Preclinical | Respiratory | Other Respiratory | Synthetics | Small Molecule | 2013-15 IPOs | Mid Tier Pharma, 2013-15 IPOs | Worldwide | ||||||||||||||||
82 | Tag | 9/2011 | Numab | Sucampo Pharmaceuticals | 3.00 | 3.00 | 4.00 | 86.40 | 7.00 | High affinity antibodies to IL5-R/CD3 and three additional targets | Exclusive | Co-Development, License, Loan | Discovery | Unlimited | Monoclonals | 0.44 | 6.30 | 38.80 | 41.30 | 86.40 | Worldwide | ||||||||||||||
83 | Tag | 9/2011 | Opko Health | Nikon, Optos | 5.00 | 5.00 | 5.00 | 17.50 | 5.00 | Spectral OCT SLO etinal scanning device | Exclusive | Asset Purchase | Device | Ophthalmic | Other Ophthalmic | Device | 17.50 | 17.50 | Worldwide | ||||||||||||||||
84 | Tag | 9/2011 | Rockefeller University | ContraFect | 5.00 | 5.00 | 5.00 | 5.56 | 5.00 | CF-301 staphylococcal-specific lysin protein | Exclusive | Development, License | Preclinical | Infectious-Bacterial | Other Infectious-Bacterial | Recombinant DNA | 0.56 | 5.00 | 5.56 | Research Institution | 2013-15 IPOs | Worldwide | |||||||||||||
85 | Tag | 9/2011 | University of Central Florida | Red Hill Biopharma | 7.00 | 7.00 | 7.00 | 0.05 | 7.00 | Protocol for detection of Mycobacterium avium subspecies paratuberculosis in blood | Exclusive | Development, License | Gastrointestinal | IBD - Crohn's Disease, IBD - Other, IBD - Ulcerative Colitis | Diagnostics | 0.05 | Research Institution | Worldwide | |||||||||||||||||
86 | Tag | 7/2011 | Cubist, Merck, Trius Therapeutics | Bayer | 17.00 | 17.00 | 17.00 | 94.10 | 17.00 | Tedizolid phosphate antibiotic (TR-701) in Asia-Pacific, Africa, Latin America and the Middle East | Exclusive | Co-Development, License | Phase III | Infectious-Bacterial | Broad Focus Infectious-Bacterial, Pneumonia | Synthetics | Small Molecule | 25.00 | 0.37 | 34.10 | 59.10 | 35.00 | Top Pharma | Top Pharma | Africa, Asia, Middle East, South America | ||||||||||
87 | Tag | 7/2011 | Durect | Zogenix | 5.00 | 6.20 | 8.35 | 105.25 | 12.00 | Relday (SR delivery of risperidone) for schizophrenia and bipolar disorder | Exclusive | Development, License, Option, Supply | Preclinical, Formulation | Psychiatric | Bipolar Disorder, Schizophrenia | Drug Delivery | Sustained Release | 2.25 | 38.00 | 40.25 | 65.00 | Worldwide | |||||||||||||
88 | Tag | 6/2011 | Halozyme Therapeutics | Intrexon | 7.00 | 9.00 | 10.00 | 77.00 | 11.00 | Subcutaneous formulation of recombinant human alpha-1 anti-trypsin for genetic emphysema | Exclusive | Development, License, Supply, Termination | Preclinical, Formulation, Orphan Indication | Other/Miscellaneous, Respiratory | Genetic Disorders, Other Respiratory | Hyaluronic acid, Recombinant DNA | 13.00 | 44.00 | 10.00 | 67.00 | 10.00 | 20.00 | 2013-15 IPOs | Worldwide | |||||||||||
89 | Tag | 6/2011 | Scolr Pharma | Syntrix | 4.00 | 4.00 | 4.00 | 0.02 | 4.00 | O-desmethyltramadol opioid for treatment of pain | Exclusive | License | Central Nervous System | Pain | Synthetics | Small Molecule | 0.02 | 0.02 | Worldwide | ||||||||||||||||
90 | Tag | 5/2011 | Halozyme Therapeutics | Shire, ViroPharma | 10.00 | 10.00 | 10.00 | 83.00 | 10.00 | CINRYZE with rHuPH20 (hyaluronidase) subcutaneous delivery for hereditary angioedema | Exclusive | Development, License, Supply | Preclinical, Formulation, Orphan Indication | Autoimmune/Inflammatory, Other/Miscellaneous | Genetic Disorders, Other Autoimmune/Inflammatory | Drug Delivery, Recombinant DNA | Transdermal | 9.00 | 44.00 | 30.00 | 83.00 | Major Biotech | Worldwide | ||||||||||||
91 | Tag | 5/2011 | Oasmia Pharmaceutical | Medison Pharma | 30.00 | 30.00 | 30.00 | 0.56 | 30.00 | Paclical for ovarian and lung cancer in Israel and Turkey | Exclusive | License, Supply | Phase III | Cancer | Lung, Ovarian | Natural Product | 0.28 | 0.28 | 0.56 | 2013-15 IPOs | Middle East | ||||||||||||||
92 | Tag | 4/2011 | Hebrew University, Yissum Research Development | Immune Pharmaceuticals | 4.50 | 4.50 | 4.50 | 15.48 | 4.50 | Antibody nanoparticle conjugates for the targeted delivery
of active agents conjugated to antibodie | Exclusive | Development, License, Research | Preclinical | Drug Delivery, Monoclonals | Human Abs | 0.03 | 1.50 | 8.55 | 5.40 | 15.48 | Research Institution | Worldwide | |||||||||||||
93 | Tag | 4/2011 | University of California, UC San Diego, Dana-Farber | Adamis Pharmaceuticals | 2.00 | 2.00 | 2.00 | 1.92 | 2.00 | Telomerase reverse transcription antigen for cancer immunization in US | Exclusive | Development, License | Phase I | Cancer | Broad Focus Cancer | Vaccines | 0.06 | 0.98 | 0.88 | 1.92 | Research Institution | NAFTA | |||||||||||||
94 | Tag | 3/2011 | Cornell University | Strongbridge Biopharma | 2.50 | 2.50 | 2.50 | 3.01 | 2.50 | Commensal bacteria as signal mediators | Exclusive | Development, License | Preclinical | 0.44 | 2.33 | 0.25 | 3.01 | Research Institution | 2013-15 IPOs | Worldwide | |||||||||||||||
95 | Tag | 2/2011 | Marina Biotech | Debio Group, Debiopharm | 10.00 | 10.00 | 11.00 | 25.60 | 14.00 | RNAi therapeutics to HRAS & FGFR3 for bladder cancer | Exclusive | License, Research, Termination | Discovery, Orphan Indication | Cancer | Bladder | Oligonucleotides | RNAi | 1.60 | 24.00 | 25.60 | Worldwide | ||||||||||||||
96 | Tag | 2/2011 | Progenics Pharmaceuticals | Valeant Pharmaceuticals, Salix Pharmaceuticals | 16.00 | 16.60 | 17.80 | 350.00 | 19.00 | Relistor (methylnaltrexone) for constipation ex-Japan | Exclusive | License | Approved | Gastrointestinal | Bowel Movement Disorders | Synthetics | Small Molecule | 60.00 | 0.36 | 40.00 | 50.00 | 150.00 | 200.00 | Mid Tier Pharma | Africa, Asia, Europe, Middle East, NAFTA, South America | ||||||||||
97 | Tag | 2/2011 | University of Miami | Heat Biologics | 5.00 | 5.00 | 5.00 | 0.05 | 5.00 | HIV/SIV Vaccine technology | Exclusive | License | Infectious-Viral | Human Immunodeficiency Virus/HIV | Vaccines | 0.05 | Research Institution | 2013-15 IPOs | Worldwide | ||||||||||||||||
98 | Tag | 2/2011 | University of Miami | Heat Biologics | 5.00 | 5.00 | 5.00 | 5.00 | Heat Shock Protein GP96 Vaccination | Exclusive | License | Vaccines | Research Institution | 2013-15 IPOs | Worldwide | ||||||||||||||||||||
99 | Tag | 2/2011 | University of Miami | Heat Biologics | 5.00 | 5.00 | 5.00 | 0.01 | 5.00 | Vaccine for treatment of non small cell lung cancer | Exclusive | License | Cancer | Lung | Vaccines | 0.01 | Research Institution | 2013-15 IPOs | Worldwide | ||||||||||||||||
100 | Tag | 2/2011 | University of Miami | Heat Biologics | 5.00 | 5.00 | 5.00 | Allogeneic Cancer Cell-based immunotherapy | Exclusive | License | Discovery | Cancer | Broad Focus Cancer | Cell Therapy - Stem Cells/Factors | Research Institution | 2013-15 IPOs | Worldwide |